28505-57-9

Upstream product

• 50-00-0 formaldehyd 
• 119-36-8 methyl salicylate 
• 69-72-7 salicylic acid 
• 67-56-1 methanol 
• 122-25-8 5,5'-methylenedisalicylic acid 

Downstream Products

• 122-25-8 5,5'-methylenedisalicylic acid 
• 1056449-47-8 dimethyl 5,5'-methylenebis(2-(3-chloro-2-methylphenylamino)benzoate) 
• 1056449-76-3 5,5'-methylenebis(2-(3-chloro-2-methylphenylamino)benzoic acid) 
• 1056452-95-9 dimethyl 5,5'-methylenebis(2-(trifluoromethylsulfonyloxy)-benzoate) 
• 443687-78-3 C₃₃H₃₀Br₂O₆ 
• 2346-44-3 4,4'-methylenebis[2-(hydroxymethyl)phenol] 
• 327028-16-0 4,4'-bis(5-bromopentoxy)-3,3'-dicarboxymethyl-4,4'-dihydroxydiphenyl-methane 

Relevant academic research and scientific papers

Targeting MgrA-mediated virulence regulation in Staphylococcus aureus

Increasing antibiotic resistance in human pathogens necessitates the development of new approaches against infections. Targeting virulence regulation at the transcriptional level represents a promising strategy yet to be explored. A global transcriptional regulator, MgrA in Staphylococcus aureus, was identified previously as a key virulence determinant. We have performed a fluorescence anisotropy (FA)-based high-throughput screen that identified 5, 5-methylenedisalicylic acid (MDSA), which blocks the DNA binding of MgrA. MDSA represses the expression of α-toxin that is up-regulated by MgrA and activates the transcription of protein A, a gene down-regulated by MgrA. MDSA alters bacterial antibiotic susceptibilities via an MgrA-dependent pathway. A mouse model of infection indicated that MDSA could attenuate S. aureus virulence. This work is a rare demonstration of utilizing small molecules to block protein-DNA interaction, thus tuning important biological regulation at the transcriptional level.

Crystallization-induced light-emission enhancement of diphenylmethane derivatives

A family of diphenylmethane derivatives has been synthesized and their luminescence properties characterized. While in solution the compounds are weakly emissive, showing no aggregation-induced emission enhancement, the crystals of three dialkyl 5,5′-methylenebis(2-hydroxybenzoate) samples exhibit intense emission. This emission enhancement upon crystallization is ascribed to particular molecular packing, which stiffens the structure of the compounds via hydrogen bonds, preventing consecutive π-π interactions.

NEW METHYLENEBISPHENYL COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION

There is provided compounds of formula (I), wherein Rx, Ry, X1, X2, L1, L2, Y1 and Y2 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of leukotriene C4 synthase is desired and/or required, and particularly in the treatment of a respiratory disorder and/or inflammation.

Methylenedisalicylic acid derivatives: New PTP1B inhibitors that confer resistance to diet-induced obesity

Methylenedisalicylic acid derivatives were synthesized and their inhibitory activities against protein tyrosine phosphatases (PTPases) examined. Two of the compounds, 8 and 9, showed Ki values of 9.4 and 6.3 μM against PTP1B, 4- and 7-fold lower values compared to those against TC-PTP. They were reversible and slow-binding inhibitors against PTP1B. When compound 8 was fed to a mouse model, the weight gain and adipocyte fat storage induced by a high-fat-diet were significantly suppressed.

Use of chemical chelators as reversal agents for drug-induced neuromuscular block

The invention relates to the use of chemical chelators for the preparation of a medicament for the reversal of drug-induced neuromuscular block, to a kit for providing neuromuscular block and its reversal, and to cyclophane derivatives having general formula (A) wherein R is (a), (b) or (c); or general formula (B) wherein X is (a), (b) or (d), or a pharmaceutically acceptable salt thereof.

Anionic cyclophanes as potential reversal agents of muscle relaxants by chemical chelation

A series of carboxyl-containing cyclophanes have been designed and synthesised as chemical chelators (or host molecules) of cationic muscle relaxant drugs (or guest molecules). Three of these cyclophane derivatives, 1-3, have been shown by NMR to form 1:1 complexes with the muscle relaxants pancuronium, 4 and gallamine, 5 in D2O, with association constants up to 104 M-1. When tested in an in vitro chick biventer muscle preparation, the cyclophanes reversed the neuromuscular block induced by pancuronium and gallamine, with 3 having the most effective reversal against pancuronium (EC50 40 μM).